Nexalin Technology (NXL) Stock Price

Nexalin Technology Price

NYSE·CLOSED
0.47USD+0.0060 (+1.29 %)
Market closed

Revenue at Nexalin Technology has contracted by 4.0% per year over the past 5 years to 168,700.00 USD. Nexalin Technology's net margin stands at -4,509.3%, down from -1,401.2% several years earlier. Analysts set a median price target of 4.08 USD, implying 771.8% above the current price. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus. Over the past year Nexalin Technology shares have lost 60.7%. The stock trades about 46% above its 52-week low.

Nexalin Technology stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Nexalin Technology over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Nexalin Technology stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Nexalin Technology's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Nexalin Technology Stock Price History
DateNexalin Technology Price
7/23/20260.47 USD
7/22/20260.46 USD
7/21/20260.48 USD
7/20/20260.49 USD
7/17/20260.48 USD
7/16/20260.45 USD
7/15/20260.47 USD
7/14/20260.41 USD
7/13/20260.40 USD
7/10/20260.46 USD
7/9/20260.45 USD
7/8/20260.42 USD
7/7/20260.36 USD
7/6/20260.37 USD
7/2/20260.36 USD
7/1/20260.38 USD
6/30/20260.33 USD
6/29/20260.34 USD
6/26/20260.35 USD
6/25/20260.34 USD
6/24/20260.33 USD
6/23/20260.36 USD
6/22/20260.38 USD
6/18/20260.37 USD
6/17/20260.39 USD
6/16/20260.39 USD
6/15/20260.40 USD
6/12/20260.43 USD
6/11/20260.47 USD
6/10/20260.46 USD
6/9/20260.45 USD
6/8/20260.50 USD
6/5/20260.52 USD
6/4/20260.54 USD
6/3/20260.53 USD
6/2/20260.55 USD
6/1/20260.58 USD
5/29/20260.61 USD
5/28/20260.58 USD
5/27/20260.56 USD
5/26/20260.48 USD
5/22/20260.38 USD
5/21/20260.40 USD
5/20/20260.34 USD
5/19/20260.32 USD
5/18/20260.32 USD
5/15/20260.34 USD
5/14/20260.34 USD
5/13/20260.34 USD
5/12/20260.34 USD
5/11/20260.34 USD
5/8/20260.35 USD
5/7/20260.34 USD
5/6/20260.35 USD
5/5/20260.36 USD
5/4/20260.38 USD
5/1/20260.38 USD
4/30/20260.35 USD
4/29/20260.35 USD
4/28/20260.37 USD
4/27/20260.41 USD
4/24/20260.43 USD
4/23/20260.43 USD
4/22/20260.47 USD
4/21/20260.44 USD
4/20/20260.47 USD
4/17/20260.46 USD
4/16/20260.46 USD
4/15/20260.51 USD
4/14/20260.43 USD
4/13/20260.43 USD
4/10/20260.40 USD
4/9/20260.38 USD
4/8/20260.35 USD
4/7/20260.37 USD
4/6/20260.36 USD
4/2/20260.35 USD
4/1/20260.35 USD
3/31/20260.35 USD
3/30/20260.35 USD
3/27/20260.36 USD
3/26/20260.38 USD
3/25/20260.40 USD
3/24/20260.41 USD
3/23/20260.41 USD
3/20/20260.43 USD
3/19/20260.40 USD
3/18/20260.41 USD
3/17/20260.41 USD
3/16/20260.41 USD
3/13/20260.42 USD
3/12/20260.41 USD
3/11/20260.43 USD
3/10/20260.43 USD
3/9/20260.46 USD
3/6/20260.44 USD
3/5/20260.44 USD
3/4/20260.44 USD
3/3/20260.45 USD
3/2/20260.45 USD
2/27/20260.47 USD
2/26/20260.52 USD
2/25/20260.50 USD
2/24/20260.56 USD
2/23/20260.49 USD
2/20/20260.50 USD
2/19/20260.46 USD
2/18/20260.43 USD
2/17/20260.40 USD
2/13/20260.45 USD
2/12/20260.45 USD
2/11/20260.48 USD
2/10/20260.54 USD
2/9/20260.52 USD
2/6/20260.51 USD
2/5/20260.62 USD
2/4/20260.57 USD
2/3/20260.57 USD
2/2/20260.57 USD
1/30/20260.57 USD
1/29/20260.57 USD
1/28/20260.60 USD
1/27/20260.59 USD
1/26/20260.60 USD
1/23/20260.61 USD
1/22/20260.63 USD
1/21/20260.62 USD
1/20/20260.63 USD
1/16/20260.69 USD
1/15/20260.69 USD
1/14/20260.74 USD
1/13/20260.68 USD
1/12/20260.71 USD
1/9/20260.71 USD
1/8/20260.71 USD
1/7/20260.75 USD
1/6/20260.76 USD
1/5/20260.64 USD
1/2/20260.58 USD
12/31/20250.56 USD
12/30/20250.54 USD
12/29/20250.61 USD
12/26/20250.63 USD
12/24/20250.69 USD
12/23/20250.72 USD
12/22/20250.77 USD
12/19/20250.83 USD
12/18/20250.81 USD
12/17/20250.80 USD
12/16/20250.81 USD
12/15/20250.82 USD
12/12/20250.92 USD
12/11/20250.99 USD
12/10/20250.98 USD
12/9/20251.00 USD
12/8/20250.96 USD
12/5/20250.97 USD
12/4/20250.96 USD
12/3/20250.99 USD
12/2/20250.97 USD
12/1/20250.92 USD
11/28/20251.08 USD
11/26/20251.08 USD
11/25/20251.06 USD
11/24/20251.09 USD
11/21/20251.01 USD
11/20/20250.98 USD
11/19/20251.05 USD
11/18/20251.06 USD
11/17/20251.08 USD
11/14/20251.08 USD
11/13/20251.17 USD
11/12/20251.26 USD
11/11/20251.24 USD
11/10/20251.34 USD
11/7/20251.31 USD
11/6/20251.25 USD
11/5/20251.32 USD
11/4/20251.38 USD
11/3/20251.47 USD
10/31/20251.50 USD
10/30/20251.53 USD
10/29/20251.55 USD
10/28/20251.48 USD
10/27/20251.48 USD
10/24/20251.44 USD
10/23/20251.48 USD
10/22/20251.51 USD
10/21/20251.54 USD
10/20/20251.68 USD
10/17/20251.52 USD
10/16/20251.33 USD
10/15/20251.45 USD
10/14/20251.29 USD
10/13/20251.34 USD
10/10/20251.28 USD
10/9/20251.50 USD
10/8/20251.86 USD
10/7/20250.94 USD
10/6/20250.93 USD
10/3/20250.91 USD
10/2/20250.92 USD
10/1/20250.88 USD
9/30/20250.92 USD
9/29/20250.95 USD
9/26/20250.94 USD
9/25/20250.96 USD
9/24/20251.02 USD
9/23/20251.02 USD
9/22/20250.96 USD
9/19/20250.94 USD
9/18/20250.79 USD
9/17/20250.81 USD
9/16/20250.84 USD
9/15/20250.85 USD
9/12/20250.88 USD
9/11/20250.87 USD
9/10/20250.81 USD
9/9/20250.81 USD
9/8/20250.83 USD
9/5/20250.84 USD
9/4/20250.85 USD
9/3/20250.84 USD
9/2/20250.94 USD
8/29/20250.96 USD
8/28/20250.92 USD
8/27/20250.81 USD
8/26/20250.85 USD
8/25/20250.83 USD
8/22/20251.02 USD
8/21/20250.73 USD
8/20/20250.72 USD
8/19/20250.75 USD
8/18/20250.80 USD
8/15/20250.78 USD
8/14/20250.81 USD
8/13/20250.84 USD
8/12/20250.88 USD
8/11/20250.89 USD
8/8/20250.90 USD
8/7/20250.93 USD
8/6/20250.99 USD
8/5/20251.02 USD
8/4/20250.99 USD
8/1/20250.99 USD
7/31/20251.00 USD
7/30/20251.03 USD
7/29/20251.07 USD
7/28/20251.13 USD
7/25/20251.16 USD
7/24/20251.19 USD
Access this data via the Eulerpool API
Get Free API Key

Nexalin Technology Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2019
207,400.00 USD
-1.47 M USD
-5.02 M USD
Jan 1, 2020
242,900.00 USD
-3.26 M USD
-3.40 M USD
Jan 1, 2021
144,100.00 USD
-6.02 M USD
-6.08 M USD
Jan 1, 2022
1.32 M USD
-1.83 M USD
-1.70 M USD
Jan 1, 2023
110,800.00 USD
-5.70 M USD
-4.65 M USD
Jan 1, 2024
168,700.00 USD
-7.75 M USD
-7.61 M USD
Jan 1, 2025 (e)
233,310.00 USD
-7.64 M USD
-9.23 M USD
Jan 1, 2026 (e)
666,600.00 USD
-8.81 M USD
-7.35 M USD

Nexalin Technology Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 24, 2026, 8:46 PM
 
REVENUEk USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
2019202020212022202320242025e2026e
–––1,000.00––––
-1.00-3.00-6.00-1.00-5.00-7.00-7.00-8.00
–––-100.00––––
-5.00-3.00-6.00-1.00-4.00-7.00-9.00-7.00
–-40.00100.00-83.33300.0075.0028.57-22.22
7.287.287.287.297.369.229.229.22
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Nexalin Technology generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Nexalin Technology retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Nexalin Technology's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Nexalin Technology has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Nexalin Technology's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Nexalin Technology stock margins

The Nexalin Technology margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Nexalin Technology. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Nexalin Technology.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2019
70.20 %
-706.94 %
-2,421.02 %
Jan 1, 2020
88.06 %
-1,341.46 %
-1,401.19 %
Jan 1, 2021
85.08 %
-4,176.68 %
-4,217.90 %
Jan 1, 2022
72.51 %
-138.72 %
-128.48 %
Jan 1, 2023
76.81 %
-5,141.07 %
-4,195.58 %
Jan 1, 2024
78.30 %
-4,596.74 %
-4,509.31 %
Jan 1, 2025 (e)
78.30 %
-3,274.46 %
-3,956.06 %
Jan 1, 2026 (e)
78.30 %
-1,321.52 %
-1,102.05 %

Nexalin Technology Stock Revenue, EBIT, Earnings per Share

The Nexalin Technology earnings per share therefore indicates how much revenue Nexalin Technology has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2019
0.03 USD
-0.20 USD
-0.69 USD
Jan 1, 2020
0.03 USD
-0.45 USD
-0.47 USD
Jan 1, 2021
0.02 USD
-0.83 USD
-0.83 USD
Jan 1, 2022
0.18 USD
-0.25 USD
-0.23 USD
Jan 1, 2023
0.02 USD
-0.77 USD
-0.63 USD
Jan 1, 2024
0.02 USD
-0.84 USD
-0.83 USD
Jan 1, 2025 (e)
0.01 USD
-0.83 USD
-0.49 USD
Jan 1, 2026 (e)
0.04 USD
-0.96 USD
-0.39 USD

Nexalin Technology business model & stock analysis

Nexalin Technology Segments

Nexalin Technology Revenue by Segment

  • 3 Years

  • Max

Device Sales
Equipment
Licensing Fee
Other
Royalty Fee
Details
Date
Device Sales
Equipment
Licensing Fee
Other
Royalty Fee
Jan 1, 2022
1.16 M USD
26,778.00 USD
79,188.00 USD
26,412.00 USD
24,479.00 USD
Jan 1, 2023
0.00 USD
27,299.00 USD
82,080.00 USD
1,369.00 USD
0.00 USD
Jan 1, 2024
55,500.00 USD
37,826.00 USD
69,501.00 USD
5,894.00 USD
0.00 USD
Jan 1, 2025
136,000.00 USD
89,042.00 USD
49,114.00 USD
27,491.00 USD
0.00 USD

Nexalin Technology Revenue by Region

  • 3 Years

  • Max

CHINA
International
United States
Details
Date
CHINA
International
United States
Jan 1, 2022
1.21 M USD
0.00 USD
113,541.00 USD
Jan 1, 2023
3,614.00 USD
0.00 USD
107,134.00 USD
Jan 1, 2024
85,248.00 USD
0.00 USD
83,473.00 USD
Jan 1, 2025
190,301.00 USD
190,301.00 USD
111,346.00 USD

Nexalin Technology Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Nexalin Technology historical P/E ratio, EBIT multiple, and P/S ratio

Nexalin Technology annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Nexalin Technology shares outstanding

The number of shares of Nexalin Technology was 9.22 M in 2025. This indicates how many shares Nexalin Technology is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2019
7.28 M Stocks
Jan 1, 2020
7.28 M Stocks
Jan 1, 2021
7.28 M Stocks
Jan 1, 2022
7.29 M Stocks
Jan 1, 2023
7.36 M Stocks
Jan 1, 2024
9.22 M Stocks
Jan 1, 2025 (e)
9.22 M Stocks
Jan 1, 2026 (e)
9.22 M Stocks

Current Nexalin Technology forecasts and price targets in July 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy80.00 % (4)
Hold20.00 % (1)
Sell0.00 % (0)
12M Price Target
4.08
Last Price
0.47
Currency
USD
12M Return Potential
771.79 %
LTM Return
0 %

Nexalin Technology Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
8/4/2026-0.10USD90,900.00USD2026 Q2
5/11/2026-0.10USD15,150.00USD2026 Q1
3/12/2026-0.12USD80,800.00USD2025 Q4
11/14/2025-0.12USD40,400.00USD2025 Q3

Nexalin Technology shareholder structure

% Name
8.23187%
Elson (Marilyn)
Elson (Marilyn)
4.28954%
MYDA Advisors LLC
MYDA Advisors LLC
2.02196%
Hu (Benjamin)
Hu (Benjamin)
1.65752%
White (Mark)
White (Mark)
0.99599%
Owens (David)
Owens (David)
0.85725%
The Vanguard Group, Inc.
The Vanguard Group, Inc.

Nexalin Technology Executives and Management Board

MW

Mr. Mark White

(64)

President, Chief Executive Officer, Director · since 2018

Compensation1.03 M USD
DO

Dr. David Owens

(64)

Chief Medical Officer, Director · since 2017

Compensation873,140.00 USD
ME

Ms. Marilyn Elson

(71)

Controller

Compensation520,000.00 USD
CS

Ms. Carolyn Shelton

(63)

Senior Vice President - Quality, Regulatory and Clinical Affairs

Compensation288,034.00 USD
LB

Ms. Leslie Bernhard

(81)

Independent Chairman of the Board

Frequently asked questions about Nexalin Technology

Analysts currently set an average price target of 4.08 USD for the Nexalin Technology stock (median: 4.08 USD), implying +771.8 % versus the latest price. The consensus is based on 5 analyst ratings.

Nexalin Technology Analyst Price Targets 2026

All fundamentals and in-depth analysis of Nexalin Technology

Our stock analysis for Nexalin Technology stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nexalin Technology. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Nexalin Technology Stock
Nexalin Technology Revenue→
Nexalin Technology Stock
Nexalin Technology Net Income→
Nexalin Technology Stock
Nexalin Technology P/E→
Nexalin Technology Stock
Nexalin Technology P/S→
Nexalin Technology Stock
Nexalin Technology EBIT→
Nexalin Technology Stock
Nexalin Technology Dividend→
Nexalin Technology Stock
Nexalin Technology Directors Dealings→
Nexalin Technology Stock
Nexalin Technology Stocks→
Nexalin Technology Stock
Nexalin Technology Market capitalization→
Nexalin Technology Stock
Nexalin Technology Debt→
Nexalin Technology Stock
Nexalin Technology Liabilities→
Nexalin Technology Stock
Nexalin Technology Equity→
Nexalin Technology Stock
Nexalin Technology AAQS→
Nexalin Technology Stock
Nexalin Technology Employees→
Nexalin Technology Stock
Nexalin Technology ROE→
Nexalin Technology Stock
Nexalin Technology ROA→
Nexalin Technology Stock
Nexalin Technology ROCE→
Nexalin Technology Stock
Nexalin Technology News→
Nexalin Technology Stock
Nexalin Technology Analyst Price Targets→

Health Stocks

NexgelNewron Pharmaceuticals SpANexien BiopharmaNewland Pharmaceutical CoNeximmuneNewcelXNexstim OyjNewCardioNextBioMedical CoNewbury PharmaceuticalsNextCell PharmaNewAmsterdam Pharma CompanyAll Stocks A–Z →